Midregional proadrenomedullin for prediction of cardiovascular events in coronary artery disease: results from the AtheroGene study
Standard
Midregional proadrenomedullin for prediction of cardiovascular events in coronary artery disease: results from the AtheroGene study. / Wild, Philipp S; Schnabel, Renate B; Lubos, Edith; Zeller, Tanja; Sinning, Christoph R; Keller, Till; Tzikas, Stergios; Lackner, Karl J; Peetz, Dirk; Rupprecht, Hans J; Bickel, Christoph; Morgenthaler, Nils G; Papassotiriou, Jana; Tiret, Laurence; Münzel, Thomas; Blankenberg, Stefan.
In: CLIN CHEM, Vol. 58, No. 1, 01.2012, p. 226-236.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Midregional proadrenomedullin for prediction of cardiovascular events in coronary artery disease: results from the AtheroGene study
AU - Wild, Philipp S
AU - Schnabel, Renate B
AU - Lubos, Edith
AU - Zeller, Tanja
AU - Sinning, Christoph R
AU - Keller, Till
AU - Tzikas, Stergios
AU - Lackner, Karl J
AU - Peetz, Dirk
AU - Rupprecht, Hans J
AU - Bickel, Christoph
AU - Morgenthaler, Nils G
AU - Papassotiriou, Jana
AU - Tiret, Laurence
AU - Münzel, Thomas
AU - Blankenberg, Stefan
PY - 2012/1
Y1 - 2012/1
N2 - BACKGROUND: Midregional proadrenomedullin (MR-proADM) is a newly identified prognostic marker in heart failure. We evaluated the prognostic impact of MR-proADM in a cohort of patients with symptomatic coronary artery disease according to their clinical presentation.METHODS: We measured baseline MR-proADM concentrations in 2240 individuals from the prospective AtheroGene study and evaluated the prognostic impact on future fatal and nonfatal cardiovascular events during a follow-up period of 3.6 (1.6) years.RESULTS: The sample comprised 1355 individuals with stable angina pectoris (SAP) and 885 with acute coronary syndrome (ACS). A cardiovascular event occurred in 192 people. Individuals presenting with SAP had only slightly lower plasma MR-proADM concentrations than those with ACS (0.53 vs 0.55 nmol/L, P=0.006). MR-proADM showed a moderate association with age, serum N-terminal pro-B-type natriuretic peptide (NT-proBNP), glomerular filtration rate, serum C-reactive protein, hypertension, diabetes, and prevalent multivessel disease (all P<0.0005). Individuals suffering from a cardiovascular event had higher MR-proADM concentrations at baseline in both groups (SAP 0.63 vs 0.53 nmol/L and ACS 0.65 nmol/L vs 0.55 nmol/L, both P<0.0005). Cox regression analysis incorporating various variables of cardiovascular risk and NT-proBNP revealed a hazard ratio of 1.4 (95% CI 1.2-1.6; P<0.0005) per increment of MR-proADM by 1SD. In risk models for secondary prevention, MR-proADM provided information comparable to that of NT-proBNP.CONCLUSIONS: MR-proADM is an independent predictor for future cardiovascular events in patients with symptomatic coronary artery disease, providing information comparable to NT-proBNP for secondary risk stratification.
AB - BACKGROUND: Midregional proadrenomedullin (MR-proADM) is a newly identified prognostic marker in heart failure. We evaluated the prognostic impact of MR-proADM in a cohort of patients with symptomatic coronary artery disease according to their clinical presentation.METHODS: We measured baseline MR-proADM concentrations in 2240 individuals from the prospective AtheroGene study and evaluated the prognostic impact on future fatal and nonfatal cardiovascular events during a follow-up period of 3.6 (1.6) years.RESULTS: The sample comprised 1355 individuals with stable angina pectoris (SAP) and 885 with acute coronary syndrome (ACS). A cardiovascular event occurred in 192 people. Individuals presenting with SAP had only slightly lower plasma MR-proADM concentrations than those with ACS (0.53 vs 0.55 nmol/L, P=0.006). MR-proADM showed a moderate association with age, serum N-terminal pro-B-type natriuretic peptide (NT-proBNP), glomerular filtration rate, serum C-reactive protein, hypertension, diabetes, and prevalent multivessel disease (all P<0.0005). Individuals suffering from a cardiovascular event had higher MR-proADM concentrations at baseline in both groups (SAP 0.63 vs 0.53 nmol/L and ACS 0.65 nmol/L vs 0.55 nmol/L, both P<0.0005). Cox regression analysis incorporating various variables of cardiovascular risk and NT-proBNP revealed a hazard ratio of 1.4 (95% CI 1.2-1.6; P<0.0005) per increment of MR-proADM by 1SD. In risk models for secondary prevention, MR-proADM provided information comparable to that of NT-proBNP.CONCLUSIONS: MR-proADM is an independent predictor for future cardiovascular events in patients with symptomatic coronary artery disease, providing information comparable to NT-proBNP for secondary risk stratification.
KW - Acute Coronary Syndrome/diagnosis
KW - Adrenomedullin/blood
KW - Aged
KW - Angina Pectoris/diagnosis
KW - Biomarkers/blood
KW - Coronary Artery Disease/diagnosis
KW - Female
KW - Humans
KW - Immunoassay
KW - Kaplan-Meier Estimate
KW - Luminescent Measurements
KW - Male
KW - Middle Aged
KW - Natriuretic Peptide, Brain/blood
KW - Peptide Fragments/blood
KW - Predictive Value of Tests
KW - Prognosis
KW - Prospective Studies
KW - Protein Precursors/blood
KW - Risk Assessment
U2 - 10.1373/clinchem.2010.157842
DO - 10.1373/clinchem.2010.157842
M3 - SCORING: Journal article
C2 - 22065157
VL - 58
SP - 226
EP - 236
JO - CLIN CHEM
JF - CLIN CHEM
SN - 0009-9147
IS - 1
ER -
